{"transactions":[{"id":691670,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":10.39,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691669,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":104.68,"value":1046800.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":9360,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691668,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":104.38,"value":835040.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":19360,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691667,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":104.47,"value":522350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691666,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.39,"value":51950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":726441,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:00:06.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283136/ownership.xml","form_type":"4"}},{"id":758407,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:56:32.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000068","document":"wk-form4_1780091789.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000068/wk-form4_1780091789.xml","form_type":"4"}},{"id":977711,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-08T23:09:43.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":7000,"derivative":{"exercise_price":14.18,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-25-311505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525311505/ownership.xml","form_type":"4"}},{"id":977710,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T23:09:43.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":2252,"price":90.3035,"value":203363.482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-311505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525311505/ownership.xml","form_type":"4"}},{"id":977709,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T23:09:43.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":2748,"price":89.323,"value":245459.604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $89.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2252,"source":{"system":"sec-edgar","filing":"0001193125-25-311505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525311505/ownership.xml","form_type":"4"}},{"id":977708,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T23:09:43.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":14.18,"value":70900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001193125-25-311505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525311505/ownership.xml","form_type":"4"}},{"id":1019333,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-14T11:55:32.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":10.34,"expiration_date":"2030-09-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-25-238130","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525238130/ownership.xml","form_type":"4"}},{"id":1019332,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T11:55:32.000Z","date":"2025-10-13","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":59.1898,"value":295949.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-238130","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525238130/ownership.xml","form_type":"4"}},{"id":1019331,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T11:55:32.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.34,"value":51700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001193125-25-238130","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525238130/ownership.xml","form_type":"4"}},{"id":1083847,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":106.14,"underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083846,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":63.66,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083845,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083844,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":100.13,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083843,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":54.13,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083842,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":86.6,"underlying":"Common Stock","underlying_shares":110500},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083841,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":170000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":81.44,"underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083840,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":36.05,"underlying":"Common Stock","underlying_shares":92500},"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083839,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":144755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1083838,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T19:44:02.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5777,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration."}],"balance_after":144755,"source":{"system":"sec-edgar","filing":"0001104659-25-069377","document":"tm2521348-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069377/tm2521348-1_4seq1.xml","form_type":"4"}},{"id":1101119,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T01:00:14.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":46.47,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-090585","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025090585/ownership.xml","form_type":"4"}},{"id":1102360,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:28:02.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":3902,"price":128.12,"value":499924.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":150532,"source":{"system":"sec-edgar","filing":"0001415889-25-018086","document":"form4-06242025_080659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925018086/form4-06242025_080659.xml","form_type":"4"}},{"id":1125225,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-03T22:30:03.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":false,"shares":6349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":5000,"derivative":{"exercise_price":10.34,"expiration_date":"2030-09-03","underlying":"Common Stock","underlying_shares":6349},"source":{"system":"sec-edgar","filing":"0000950170-25-081198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081198/ownership.xml","form_type":"4"}},{"id":1125224,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-03T22:30:03.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":6349,"price":49,"value":311101.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-081198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081198/ownership.xml","form_type":"4"}},{"id":1125223,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-03T22:30:03.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":true,"shares":6349,"price":10.34,"value":65648.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person."}],"balance_after":6349,"source":{"system":"sec-edgar","filing":"0000950170-25-081198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081198/ownership.xml","form_type":"4"}},{"id":1127180,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:34:34.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000064","document":"wk-form4_1748896459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000064/wk-form4_1748896459.xml","form_type":"4"}},{"id":1130224,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-29T16:20:07.000Z","date":"2025-05-27","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":92500,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-25-014862","document":"form4-05292025_040502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925014862/form4-05292025_040502.xml","form_type":"4"}},{"id":1130223,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T16:20:07.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":650,"price":101.93,"value":66254.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $101.53 to $102.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":146630,"source":{"system":"sec-edgar","filing":"0001415889-25-014862","document":"form4-05292025_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925014862/form4-05292025_040502.xml","form_type":"4"}},{"id":1130222,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T16:20:07.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":4350,"price":101.02,"value":439437.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $100.42 to $101.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":147280,"source":{"system":"sec-edgar","filing":"0001415889-25-014862","document":"form4-05292025_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925014862/form4-05292025_040502.xml","form_type":"4"}},{"id":1130221,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T16:20:07.000Z","date":"2025-05-27","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.05,"value":180250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":151630,"source":{"system":"sec-edgar","filing":"0001415889-25-014862","document":"form4-05292025_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925014862/form4-05292025_040502.xml","form_type":"4"}},{"id":1203333,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-17T16:26:03.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":5766,"price":88.8,"value":512020.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":146630,"source":{"system":"sec-edgar","filing":"0001415889-25-008211","document":"form4-03172025_080359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925008211/form4-03172025_080359.xml","form_type":"4"}},{"id":1205418,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-14T16:36:19.000Z","date":"2025-03-12","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":97500,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-25-008112","document":"form4-03142025_080315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925008112/form4-03142025_080315.xml","form_type":"4"}},{"id":1205417,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-14T16:36:19.000Z","date":"2025-03-12","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":88.37,"value":159066.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.22 to $88.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":152396,"source":{"system":"sec-edgar","filing":"0001415889-25-008112","document":"form4-03142025_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925008112/form4-03142025_080315.xml","form_type":"4"}},{"id":1205416,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-14T16:36:19.000Z","date":"2025-03-12","kind":"sale","planned":true,"acquired":false,"shares":5700,"price":87.62,"value":499434.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.22 to $88.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":154196,"source":{"system":"sec-edgar","filing":"0001415889-25-008112","document":"form4-03142025_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925008112/form4-03142025_080315.xml","form_type":"4"}},{"id":1205415,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-14T16:36:19.000Z","date":"2025-03-12","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":36.05,"value":270375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":159896,"source":{"system":"sec-edgar","filing":"0001415889-25-008112","document":"form4-03142025_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925008112/form4-03142025_080315.xml","form_type":"4"}},{"id":1296194,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-23T19:53:02.000Z","date":"2025-01-21","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":105000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-001989","document":"form4-01242025_120158.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001989/form4-01242025_120158.xml","form_type":"4"}},{"id":1296193,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T19:53:02.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":200,"price":110.61,"value":22122.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":152396,"source":{"system":"sec-edgar","filing":"0001415889-25-001989","document":"form4-01242025_120158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001989/form4-01242025_120158.xml","form_type":"4"}},{"id":1296192,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T19:53:02.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":7400,"price":109.92,"value":813408.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.55 to $110.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":152596,"source":{"system":"sec-edgar","filing":"0001415889-25-001989","document":"form4-01242025_120158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001989/form4-01242025_120158.xml","form_type":"4"}},{"id":1296191,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T19:53:02.000Z","date":"2025-01-21","kind":"sale","planned":true,"acquired":false,"shares":7561,"price":109.11,"value":824980.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.55 to $109.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":159996,"source":{"system":"sec-edgar","filing":"0001415889-25-001989","document":"form4-01242025_120158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001989/form4-01242025_120158.xml","form_type":"4"}},{"id":1296190,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T19:53:02.000Z","date":"2025-01-21","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":36.05,"value":360500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":167557,"source":{"system":"sec-edgar","filing":"0001415889-25-001989","document":"form4-01242025_120158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001989/form4-01242025_120158.xml","form_type":"4"}},{"id":1302305,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-15T18:04:52.000Z","date":"2025-01-13","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":115000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-25-001507","document":"form4-01152025_110148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001507/form4-01152025_110148.xml","form_type":"4"}},{"id":1302304,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T18:04:52.000Z","date":"2025-01-13","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":102.28,"value":511400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $102.00 to $102.44 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":157557,"source":{"system":"sec-edgar","filing":"0001415889-25-001507","document":"form4-01152025_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001507/form4-01152025_110148.xml","form_type":"4"}},{"id":1302303,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T18:04:52.000Z","date":"2025-01-13","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.05,"value":180250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":162557,"source":{"system":"sec-edgar","filing":"0001415889-25-001507","document":"form4-01152025_110148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925001507/form4-01152025_110148.xml","form_type":"4"}},{"id":1323879,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":36.05,"value":540750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":120000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1323878,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":91.96,"value":193116.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.84 to $92.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":157557,"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1323877,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"sale","planned":true,"acquired":false,"shares":3800,"price":91.15,"value":346370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.79 to $91.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":159657,"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1323876,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"sale","planned":true,"acquired":false,"shares":5180,"price":89.01,"value":461071.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.63 to $89.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":163457,"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1323875,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"sale","planned":true,"acquired":false,"shares":3920,"price":88.28,"value":346057.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.60 to $88.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":168637,"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1323874,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T16:15:09.000Z","date":"2024-12-19","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":36.05,"value":540750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":172557,"source":{"system":"sec-edgar","filing":"0001415889-24-029971","document":"form4-12202024_041206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924029971/form4-12202024_041206.xml","form_type":"4"}},{"id":1368205,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-12T16:15:05.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":135000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-026594","document":"form4-11122024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924026594/form4-11122024_041101.xml","form_type":"4"}},{"id":1368204,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T16:15:05.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":102,"value":510000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":157557,"source":{"system":"sec-edgar","filing":"0001415889-24-026594","document":"form4-11122024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924026594/form4-11122024_041101.xml","form_type":"4"}},{"id":1368203,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T16:15:05.000Z","date":"2024-11-07","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.05,"value":180250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":162557,"source":{"system":"sec-edgar","filing":"0001415889-24-026594","document":"form4-11122024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924026594/form4-11122024_041101.xml","form_type":"4"}},{"id":1370830,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:53:52.000Z","date":"2024-11-06","kind":"sale","planned":true,"acquired":false,"shares":6700,"price":36.7631,"value":246312.77,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $36.48 to $37.00, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27360,"source":{"system":"sec-edgar","filing":"0001636282-24-000089","document":"wk-form4_1731102826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000089/wk-form4_1731102826.xml","form_type":"4"}},{"id":1380549,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-28T20:41:05.000Z","date":"2024-10-25","kind":"sale","planned":true,"acquired":false,"shares":300,"price":36.43,"value":10929.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2024."}],"balance_after":34060,"source":{"system":"sec-edgar","filing":"0001636282-24-000070","document":"wk-form4_1730148059.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000070/wk-form4_1730148059.xml","form_type":"4"}},{"id":1409431,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-11T16:06:41.000Z","date":"2024-09-09","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":140000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-023204","document":"form4-09112024_080936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924023204/form4-09112024_080936.xml","form_type":"4"}},{"id":1409430,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T16:06:41.000Z","date":"2024-09-09","kind":"sale","planned":true,"acquired":false,"shares":7734,"price":85.12,"value":658318.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.78 to $85.56 per share."}],"balance_after":157557,"source":{"system":"sec-edgar","filing":"0001415889-24-023204","document":"form4-09112024_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924023204/form4-09112024_080936.xml","form_type":"4"}},{"id":1409429,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T16:06:41.000Z","date":"2024-09-09","kind":"sale","planned":true,"acquired":false,"shares":11968,"price":85.86,"value":1027572.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.59 to $86.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (3) in this form 4."}],"balance_after":165291,"source":{"system":"sec-edgar","filing":"0001415889-24-023204","document":"form4-09112024_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924023204/form4-09112024_080936.xml","form_type":"4"}},{"id":1409428,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T16:06:41.000Z","date":"2024-09-09","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":36.05,"value":360500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 8, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":177259,"source":{"system":"sec-edgar","filing":"0001415889-24-023204","document":"form4-09112024_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924023204/form4-09112024_080936.xml","form_type":"4"}},{"id":1423337,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-26T22:31:05.000Z","date":"2024-08-26","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":11349,"derivative":{"exercise_price":10.34,"expiration_date":"2030-07-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-24-100660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024100660/ownership.xml","form_type":"4"}},{"id":1423336,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T22:31:05.000Z","date":"2024-08-26","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":49.1017,"value":245508.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-100660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024100660/ownership.xml","form_type":"4"}},{"id":1423335,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T22:31:05.000Z","date":"2024-08-26","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.34,"value":51700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-24-100660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024100660/ownership.xml","form_type":"4"}},{"id":1473319,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T21:00:13.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-075712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024075712/ownership.xml","form_type":"4"}},{"id":1478485,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T17:41:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016987","document":"form4-06142024_090629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016987/form4-06142024_090629.xml","form_type":"4"}},{"id":1478484,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T17:41:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":167259,"source":{"system":"sec-edgar","filing":"0001415889-24-016987","document":"form4-06142024_090629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016987/form4-06142024_090629.xml","form_type":"4"}},{"id":1513787,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-16T20:10:22.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":11323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":11323,"derivative":{"exercise_price":39.29,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":11323},"source":{"system":"sec-edgar","filing":"0000950170-24-061082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024061082/ownership.xml","form_type":"4"}},{"id":1560350,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-26T21:11:07.000Z","date":"2024-03-07","kind":"sale","planned":false,"acquired":false,"shares":11033,"price":90.69,"value":1000582.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":165017,"source":{"system":"sec-edgar","filing":"0001415889-24-009169","document":"form4-03272024_010359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009169/form4-03272024_010359.xml","form_type":"4"}},{"id":1563063,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on February 3, 2016 and is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":15.01,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563062,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":false,"shares":15073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on July 30, 2014 and is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.87,"expiration_date":"2024-07-30","underlying":"Common Stock","underlying_shares":15073},"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563061,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":1367,"price":89.12,"value":121827.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $88.94 to $89.41 per share."}],"balance_after":176050,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563060,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":6285,"price":88.6,"value":556851.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $87.93 to $88.92 per share."}],"balance_after":177417,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563059,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":8440,"price":87.26,"value":736474.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $86.80 to $87.79 per share."}],"balance_after":183702,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563058,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":6251,"price":86.46,"value":540461.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.80 to $86.79 per share."}],"balance_after":192142,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563057,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":2730,"price":85.22,"value":232650.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.80 to $85.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6)."}],"balance_after":198393,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563056,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":15.01,"value":150100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":201123,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1563055,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T17:50:39.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":15073,"price":1.87,"value":28186.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":191123,"source":{"system":"sec-edgar","filing":"0001415889-24-009009","document":"form4-03222024_090329.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924009009/form4-03222024_090329.xml","form_type":"4"}},{"id":1629595,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-21","kind":"exercise","planned":true,"acquired":false,"shares":4385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":16349,"derivative":{"exercise_price":10.34,"expiration_date":"2030-07-28","underlying":"Common Stock","underlying_shares":4385},"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1629594,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-20","kind":"exercise","planned":true,"acquired":false,"shares":615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":20734,"derivative":{"exercise_price":10.34,"expiration_date":"2030-07-28","underlying":"Common Stock","underlying_shares":615},"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1629593,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":4385,"price":39.0483,"value":171226.7955,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1629592,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-21","kind":"exercise","planned":true,"acquired":true,"shares":4385,"price":10.34,"value":45340.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."}],"balance_after":4385,"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1629591,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":615,"price":39.0746,"value":24030.879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1629590,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-21T23:46:13.000Z","date":"2024-02-20","kind":"exercise","planned":true,"acquired":true,"shares":615,"price":10.34,"value":6359.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."}],"balance_after":615,"source":{"system":"sec-edgar","filing":"0000950170-24-018246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024018246/ownership.xml","form_type":"4"}},{"id":1667937,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 3, 2016 and is fully vested as of the date hereof."}],"balance_after":2496,"derivative":{"exercise_price":15.01,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667936,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on July 30, 2014 and is fully vested as of the date hereof."}],"balance_after":15073,"derivative":{"exercise_price":1.87,"expiration_date":"2024-07-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667935,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":100,"price":83.57,"value":8357.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":176050,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667934,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":7924,"price":82.76,"value":655790.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.42 to $83.24 per share."}],"balance_after":176150,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667933,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":10890,"price":81.7,"value":889713.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $81.42 to $82.41 per share."}],"balance_after":184074,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667932,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":6086,"price":81.16,"value":493939.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $80.42 to $81.41 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4)."}],"balance_after":194964,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667931,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":15.01,"value":150100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":201050,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1667930,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T18:13:22.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.87,"value":28050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":191050,"source":{"system":"sec-edgar","filing":"0001415889-24-001931","document":"form4-01292024_110112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924001931/form4-01292024_110112.xml","form_type":"4"}},{"id":1673152,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T00:37:29.000Z","date":"2024-01-23","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":21349,"derivative":{"exercise_price":10.34,"expiration_date":"2030-07-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-24-006766","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024006766/ownership.xml","form_type":"4"}},{"id":1673151,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-24T00:37:29.000Z","date":"2024-01-23","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":30.047,"value":300470.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-006766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024006766/ownership.xml","form_type":"4"}},{"id":1673150,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-24T00:37:29.000Z","date":"2024-01-23","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":10.34,"value":103400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-24-006766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024006766/ownership.xml","form_type":"4"}},{"id":1712108,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-13T15:56:07.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2017 and is fully vested as of the transaction date."}],"balance_after":150000,"derivative":{"exercise_price":36.05,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-23-016360","document":"form4-12132023_081200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923016360/form4-12132023_081200.xml","form_type":"4"}},{"id":1712107,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T15:56:07.000Z","date":"2023-12-11","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":79.07,"value":395350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $79.00 to $79.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":176050,"source":{"system":"sec-edgar","filing":"0001415889-23-016360","document":"form4-12132023_081200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923016360/form4-12132023_081200.xml","form_type":"4"}},{"id":1712106,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T15:56:07.000Z","date":"2023-12-11","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.05,"value":180250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on May 26, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":181050,"source":{"system":"sec-edgar","filing":"0001415889-23-016360","document":"form4-12132023_081200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923016360/form4-12132023_081200.xml","form_type":"4"}},{"id":1717431,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-12-08T21:07:38.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":859,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34360},"source":{"system":"sec-edgar","filing":"0000950170-23-069048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023069048/ownership.xml","form_type":"4/A","original_submission_date":"2023-11-27"}}],"next_cursor":"2023-12-08T21:07:38.000000Z,1717431"}